• This non-dilutive financing allows OPM to continue the clinical development of OPM-101 and support the development of its product portfolio and technologies
• This agreement, strategic and unique, highlights:
– the strength of regional financing and the geographical anchoring of OPM
– the trust of the ecosystem in the OPM project
• This financing strengthens the visibility of OPM with a cash position of 13.35 million euros as of 03/10/2023
Dijon (France), October 5, 2023 at 6:00 p.m. CEST – Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces the conclusion of a financing agreement amounting to €6 million granted by three regional banks: Caisse d’Épargne Bourgogne Franche Comté, Crédit Agricole Champagne Bourgogne and Société Générale. This financing is guaranteed by Bpifrance and PCG
To receive information from ONCODESIGN PRECISION MEDICINE (OPM) in real time, send a request to [email protected]